In the BioHarmony Drug Report Database
Volanesorsen
Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
Trade Name
|
Waylivra |
|---|---|
Common Name
|
volanesorsen |
ChEMBL ID
|
CHEMBL3544994 |
Indication
|
hyperlipoproteinemia type i |
Drug Class
|
Antisense oligonucleotides |
Image (chem structure or protein)